162 related articles for article (PubMed ID: 22913733)
1. Exploring the predictive value of the evoked potentials score in MS within an appropriate patient population: a hint for an early identification of benign MS?
Margaritella N; Mendozzi L; Garegnani M; Nemni R; Colicino E; Gilardi E; Pugnetti L
BMC Neurol; 2012 Aug; 12():80. PubMed ID: 22913733
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of multimodal evoked potentials in multiple sclerosis: the EP score.
Invernizzi P; Bertolasi L; Bianchi MR; Turatti M; Gajofatto A; Benedetti MD
J Neurol; 2011 Nov; 258(11):1933-9. PubMed ID: 21479648
[TBL] [Abstract][Full Text] [Related]
3. Multimodal evoked potentials for functional quantification and prognosis in multiple sclerosis.
Giffroy X; Maes N; Albert A; Maquet P; Crielaard JM; Dive D
BMC Neurol; 2016 Jun; 16():83. PubMed ID: 27245221
[TBL] [Abstract][Full Text] [Related]
4. Early abnormalities of evoked potentials and future disability in patients with multiple sclerosis.
Kallmann BA; Fackelmann S; Toyka KV; Rieckmann P; Reiners K
Mult Scler; 2006 Feb; 12(1):58-65. PubMed ID: 16459720
[TBL] [Abstract][Full Text] [Related]
5. Early disturbances in multimodal evoked potentials as a prognostic factor for long-term disability in relapsing-remitting multiple sclerosis patients.
London F; El Sankari S; van Pesch V
Clin Neurophysiol; 2017 Apr; 128(4):561-569. PubMed ID: 28231474
[TBL] [Abstract][Full Text] [Related]
6. Multimodal evoked potentials follow up in multiple sclerosis patients under fingolimod therapy.
Iodice R; Carotenuto A; Dubbioso R; Cerillo I; Santoro L; Manganelli F
J Neurol Sci; 2016 Jun; 365():143-6. PubMed ID: 27206893
[TBL] [Abstract][Full Text] [Related]
7. Combined evoked potentials as markers and predictors of disability in early multiple sclerosis.
Schlaeger R; D'Souza M; Schindler C; Grize L; Kappos L; Fuhr P
Clin Neurophysiol; 2012 Feb; 123(2):406-10. PubMed ID: 21778106
[TBL] [Abstract][Full Text] [Related]
8. Monitoring multiple sclerosis by multimodal evoked potentials: Numerically versus ordinally scaled scoring systems.
Schlaeger R; Hardmeier M; D'Souza M; Grize L; Schindler C; Kappos L; Fuhr P
Clin Neurophysiol; 2016 Mar; 127(3):1864-71. PubMed ID: 26754876
[TBL] [Abstract][Full Text] [Related]
9. The EP-score to assess treatment efficacy in RRMS patients: a preliminary study.
Margaritella N; Mendozzi L; Garegnani M; Nemni R; Gilardi E; Pugnetti L
Int J Neurosci; 2015 Jan; 125(1):38-42. PubMed ID: 24628579
[TBL] [Abstract][Full Text] [Related]
10. Evoked potentials and disability in multiple sclerosis: A different perspective to a neglected method.
Kiylioglu N; Parlaz AU; Akyildiz UO; Tataroglu C
Clin Neurol Neurosurg; 2015 Jun; 133():11-7. PubMed ID: 25819634
[TBL] [Abstract][Full Text] [Related]
11. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
12. Prediction of MS disability by multimodal evoked potentials: investigation during relapse or in the relapse-free interval?
Schlaeger R; D'Souza M; Schindler C; Grize L; Kappos L; Fuhr P
Clin Neurophysiol; 2014 Sep; 125(9):1889-92. PubMed ID: 24555924
[TBL] [Abstract][Full Text] [Related]
13. The utility of multimodal evoked potentials in multiple sclerosis prognostication.
Ramanathan S; Lenton K; Burke T; Gomes L; Storchenegger K; Yiannikas C; Vucic S
J Clin Neurosci; 2013 Nov; 20(11):1576-81. PubMed ID: 23827173
[TBL] [Abstract][Full Text] [Related]
14. [Clinical characteristics and neurophysiologic findings in patients with multiple sclerosis without oligoclonal IgG in cerebrospinal fluid].
Mesaros S; Drulović J; Lević Z
Srp Arh Celok Lek; 2003; 131(3-4):122-6. PubMed ID: 14608874
[TBL] [Abstract][Full Text] [Related]
15. Do evoked potentials contribute to the functional follow-up and clinical prognosis of multiple sclerosis?
Giffroy X; Maes N; Albert A; Maquet P; Crielaard JM; Dive D
Acta Neurol Belg; 2017 Mar; 117(1):53-59. PubMed ID: 27194163
[TBL] [Abstract][Full Text] [Related]
16. Prediction of long-term disability in multiple sclerosis.
Schlaeger R; D'Souza M; Schindler C; Grize L; Dellas S; Radue EW; Kappos L; Fuhr P
Mult Scler; 2012 Jan; 18(1):31-8. PubMed ID: 21868486
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal follow-up of "benign" multiple sclerosis at 20 years.
Sayao AL; Devonshire V; Tremlett H
Neurology; 2007 Feb; 68(7):496-500. PubMed ID: 17296915
[TBL] [Abstract][Full Text] [Related]
18. Multimodal evoked potentials measure and predict disability progression in early relapsing-remitting multiple sclerosis.
Jung P; Beyerle A; Ziemann U
Mult Scler; 2008 May; 14(4):553-6. PubMed ID: 18562509
[TBL] [Abstract][Full Text] [Related]
19. Combined visual and motor evoked potentials predict multiple sclerosis disability after 20 years.
Schlaeger R; Schindler C; Grize L; Dellas S; Radue EW; Kappos L; Fuhr P
Mult Scler; 2014 Sep; 20(10):1348-54. PubMed ID: 24574192
[TBL] [Abstract][Full Text] [Related]
20. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
